Veradermics, Inc: management transactions · United States · SEC (Form 4)

About Veradermics, Inc

Veradermics, Inc. is a U.S.-listed biopharmaceutical company trading on the NYSE under the ticker MANE. Headquartered in New Haven, Connecticut, United States, the company was founded by dermatologists and clinical-development specialists with a clear mission: to bring more rigorous, evidence-based solutions to dermatology and aesthetic conditions that have long been underserved by proven therapies. Veradermics is now positioned as a late clinical-stage company, with its strategy centered on high-value dermatologic indications where the unmet need remains significant and the competitive standard of care is still fragmented. ([veradermics.com](https://www.veradermics.com/about?utm_source=openai)) The company’s core story is VDPHL01, its lead program for pattern hair loss. VDPHL01 is an oral, non-hormonal, extended-release minoxidil tablet designed to prolong exposure at the hair follicle while avoiding concentration spikes that may be associated with cardiovascular effects. Veradermics is developing the asset as a potentially differentiated treatment for both men and women, and it highlights the very large addressable market in the United States, where pattern hair loss affects tens of millions of people. The program is being advanced through multiple multicenter, randomized, double-blind, placebo-controlled studies, including Phase 2/3 and Phase 3 trials. ([veradermics.com](https://www.veradermics.com/pipeline?utm_source=openai)) From a competitive standpoint, Veradermics is targeting a market with limited, inconsistent, and often suboptimal treatment options. That creates room for a company that can combine dermatology expertise, clinical proof, and a formulation designed specifically for the condition rather than repurposed from another indication. The company emphasizes its physician-led origin, its understanding of patient needs in the exam room, and its focus on turning difficult-to-treat aesthetic and dermatologic problems into simpler, more reliable care. Beyond VDPHL01, Veradermics also describes an exploratory pipeline in alopecia areata, common warts, and molluscum contagiosum, which could offer future diversification if development progresses successfully. ([veradermics.com](https://www.veradermics.com/about-us/board-of-directors/?utm_source=openai)) Recent milestones point to a company moving through a catalyst-rich period. Veradermics completed its IPO on the NYSE in February 2026, raising substantial capital for commercial launch activities, manufacturing expansion, clinical development, and general corporate purposes. In 2025 and 2026, the company also disclosed ongoing clinical progress, including completion of enrollment in its second pivotal Phase 3 trial for male pattern hair loss and additional updates for the female program. For investors, the equity case remains highly execution-dependent: the key drivers are clinical readouts, regulatory milestones, and ultimately the commercial adoption potential of VDPHL01 in the United States. ([ir.veradermics.com](https://ir.veradermics.com/news-releases/news-release-details/veradermics-announces-closing-full-exercise-underwriters-option?utm_source=openai))